
Biofrontera (BFRI) Stock Forecast & Price Target
Biofrontera (BFRI) Analyst Ratings
Bulls say
Biofrontera Inc is poised for potential revenue acceleration due to the anticipated market introduction of new indications for treatments targeting superficial Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027. The expansion of their salesforce, alongside favorable reimbursement strategies, is expected to enhance the competitive positioning of Ameluz against cryotherapy, ultimately converting more customers to photodynamic therapy. Additionally, historic sales patterns indicate that the fourth quarter will be critical for revenue growth, supported by revised labeling that allows for increased dosages of Ameluz per treatment session.
Bears say
Biofrontera's stock outlook is negatively impacted by its revenue performance, with reported revenue of $8.6 million falling short of both internal estimates of $10.6 million and consensus forecasts, indicating potential operational weaknesses. Additionally, there are concerns regarding regulatory uncertainties that could adversely affect revenue generation and increase operational costs. The anticipated trading valuation for Biofrontera has been significantly revised down to $2.75 per share from a previous target of $7, reflecting a lack of confidence in the company's ability to meet future expectations.
This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.
Biofrontera (BFRI) Analyst Forecast & Price Prediction
Start investing in Biofrontera (BFRI)
Order type
Buy in
Order amount
Est. shares
0 shares